Idiopathic intracranial hypertension raises pressure around the brain, causes disabling headaches, and threatens sight. Weight loss is the established treatment, which is why these drugs were tried. What the evidence suggests is stranger and more interesting than that, and thinner than the numbers make it look — the same distance between an effect size and the design underneath it that runs through what a combination adds.
What was pooled
A 2025 systematic review included two clinical studies — one randomized trial and one non-randomized case-control — and two registries, covering 1,550 patients of whom 768 received a GLP-1 or dual GIP/GLP-1 agonist [1].
Against standard care, treated patients had a relative risk of 0.25 for papilledema (95% CI 0.15 to 0.43) and 0.41 for visual disturbance or blindness (95% CI 0.18 to 0.92). Headache risk showed a near-significant trend at 0.61 (95% CI 0.34 to 1.07). Monthly headache days fell by 3.64 at three months and 4.82 by the end of follow-up.
The result that does not fit weight loss
No association was detected between these drugs and BMI in this population. That is the most interesting line in the review, because the whole rationale for trying them was that weight loss lowers intracranial pressure.
If the benefit is real and the weight change is not, something else is doing the work — possibly an effect on cerebrospinal fluid secretion, which is a mechanism proposed for this drug class and not established in humans. A mechanism nobody has identified is also a mechanism whose limits nobody can predict, so this cuts both ways.
What it cost
Gastrointestinal side effects affected 88% of treated patients. No serious adverse events and no treatment discontinuations were reported across the included studies, which is unusual and probably reflects the size and the settings rather than a gentler experience.
For a condition that threatens sight, an 88% rate of nausea may well be an acceptable trade. It is a different calculation from the one a reader makes about weight, and it is worth making explicitly rather than assuming the tolerability figures from the head-to-head safety comparison transfer.
Where this leaves a buyer
Nowhere near a storefront. This is a neurological condition diagnosed by imaging and lumbar puncture and monitored by an ophthalmologist watching the optic disc, and none of that happens in a telehealth intake — the gap counted in what the adverse event database says. If intracranial hypertension is the reason for interest, the drug may genuinely help and the route to it is a neurologist rather than a subscription.